AU2006228334A1 - Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions - Google Patents

Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions Download PDF

Info

Publication number
AU2006228334A1
AU2006228334A1 AU2006228334A AU2006228334A AU2006228334A1 AU 2006228334 A1 AU2006228334 A1 AU 2006228334A1 AU 2006228334 A AU2006228334 A AU 2006228334A AU 2006228334 A AU2006228334 A AU 2006228334A AU 2006228334 A1 AU2006228334 A1 AU 2006228334A1
Authority
AU
Australia
Prior art keywords
calcitonin
subject
inflammatory disease
glucocorticoid
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006228334A
Other languages
English (en)
Inventor
Ian Macintyre
Lucia Mancini
Mauro Perretti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queen Mary University of London
Original Assignee
Queen Mary and Westfiled College University of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary and Westfiled College University of London filed Critical Queen Mary and Westfiled College University of London
Publication of AU2006228334A1 publication Critical patent/AU2006228334A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2006228334A 2005-04-01 2006-03-30 Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions Abandoned AU2006228334A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0506708.7 2005-04-01
GBGB0506708.7A GB0506708D0 (en) 2005-04-01 2005-04-01 Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions
PCT/GB2006/001183 WO2006103455A2 (en) 2005-04-01 2006-03-30 Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions

Publications (1)

Publication Number Publication Date
AU2006228334A1 true AU2006228334A1 (en) 2006-10-05

Family

ID=34586589

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006228334A Abandoned AU2006228334A1 (en) 2005-04-01 2006-03-30 Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions

Country Status (13)

Country Link
US (1) US20080160025A1 (enExample)
EP (1) EP1868627B1 (enExample)
JP (2) JP2008534566A (enExample)
KR (1) KR20080017001A (enExample)
CN (1) CN101180070A (enExample)
AU (1) AU2006228334A1 (enExample)
BR (1) BRPI0612220A2 (enExample)
CA (1) CA2603156A1 (enExample)
GB (1) GB0506708D0 (enExample)
IL (1) IL186286A0 (enExample)
MX (1) MX2007012078A (enExample)
RU (1) RU2394591C2 (enExample)
WO (1) WO2006103455A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040364A1 (en) 2010-09-21 2012-03-29 Unigene Laboratories Inc. Calcitonin products and therapies for treating inflammatory or degenerative diseases
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US9616081B2 (en) * 2013-03-27 2017-04-11 Taiho Pharmaceutical Co., Ltd. Antitumor agent including low-dose irinotecan hydrochloride hydrate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4006269A1 (de) * 1990-02-28 1991-08-29 Max Planck Gesellschaft Antikoerper gegen den tumor-nekrosefaktor-rezeptor
UA41909C2 (uk) * 1994-07-22 2001-10-15 Елі Ліллі Енд Компані Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
WO2001013957A2 (en) * 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
WO2005009949A2 (en) * 2003-06-30 2005-02-03 Merck & Co., Inc. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators

Also Published As

Publication number Publication date
CA2603156A1 (en) 2006-10-05
JP2013032360A (ja) 2013-02-14
JP2008534566A (ja) 2008-08-28
BRPI0612220A2 (pt) 2010-10-26
RU2394591C2 (ru) 2010-07-20
MX2007012078A (es) 2008-02-22
EP1868627A2 (en) 2007-12-26
CN101180070A (zh) 2008-05-14
WO2006103455A3 (en) 2007-03-01
KR20080017001A (ko) 2008-02-25
WO2006103455A2 (en) 2006-10-05
US20080160025A1 (en) 2008-07-03
EP1868627B1 (en) 2014-10-15
RU2007139888A (ru) 2009-05-10
GB0506708D0 (en) 2005-05-11
IL186286A0 (en) 2008-01-20

Similar Documents

Publication Publication Date Title
RU2769871C2 (ru) Поливалентные модуляторы регуляторных t-клеток
US20250289895A1 (en) Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
US20030223989A1 (en) CD137 agonists to treat patients with IgE-mediated conditions
KR20140041533A (ko) 치료용 개 면역글로불린 및 이를 이용하는 방법
ES2547333T3 (es) Métodos para tratar enfermedades autoinmunes
JP2025081517A (ja) 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用
CN118055767A (zh) 新颖的组合施用
JP2022501319A (ja) 抗Ｓｉｇｌｅｃ抗体、それを備える薬学的組成物及びその使用
AU752710B2 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (LT) pathway
EP1868627B1 (en) Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions
US20250122285A1 (en) Interleukin-2 muteins, fusion proteins, pharmaceutical compositions, and therapeutic applications
CN121843712A (zh) 用于治疗多发性硬化症的组合物和方法
TW202222829A (zh) 治療皮膚型紅斑狼瘡及全身性紅斑狼瘡之方法
EP4257598A1 (en) Fusion protein including glp-1 receptor agonist and anti-oscar antibody, and use thereof
JP2022524814A (ja) 抗ｌｉｎｇｏ－１抗体を含む医薬組成物
EP4622669A1 (en) Methods for improving bone growth by administering an il-4r antagonist
BR112018072125B1 (pt) Composição farmacêutica e seringa, injetor ou bomba
BR122024003611A2 (pt) Composições farmacêuticas, anticorpo anti-bdca2, uso do mesmo, e seringa ou bomba
KR20010073943A (ko) 히스톤 에이치2에이, 에이치2비 또는 그것의 단편을함유하는 류마티스 관절염 치료제 조성물

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted